Press Releases

AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind, placebo-controlled, first-in-patient clinical trial of AJ201 in adults with Spinal and Bulbar Muscular Atrophy (SBMA). Conducted across six U.S. clinical sites, the study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic

Unicon Pharma, a leading provider of compliance, validation, and workforce solutions for the life sciences industry, is excited to announce a strategic partnership with VRR Life Sciences, a Bangalore, India-based leader in Computer System Validation (CSV) and regulatory technology services. Operating under the unified brand VRR Life Sciences, a Unicon Company, this collaboration marks a significant milestone in Unicon's strategy to deliver scalable, tech-enabled compliance solut

Cybin Inc, a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, applauds recent comments made by Dr. Martin Makary, Commissioner of the U.S. FDA relating to the importance of accelerating and prioritizing research on the clinical benefits of psychedelic therapeutics. “It is gratifying that the FDA Commissioner shares our belief in the potential therapeutic value

Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, Airsupra (albuterol/budesonide), demonstrated statistically significant and clinically meaningful improvements in all primary and secondary endpoints compared to albuterol in patients with mild asthma.1,2 These data were published in the New England Journal of Medicine and presented today at the American Thoracic Society (ATS) 2025 International Conference in San Franci

Pfizer Inc. today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial efficacy and safety data in a promisin

The first patient has been dosed in the IDeate-Esophageal01 Phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus investigator’s choice of chemotherapy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) with disease progression following treatment with a platinum-containing systemic therapy and an immune checkpoint inhibitor. Ifinatamab deruxtecan is a specifically engineered, potent

Amneal Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya® (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 Brekiya autoinjector provides patients with the potential for sustained* pain relief† in a convenient, self-administered form.1,3,4 It contains

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217, pTau181, pTau231, and total tau (tTau) protein measured directly from blood samples—delivering unprecedented sensitivity and specificity for the study of neurodegenerative disea

Cybin Inc, a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has engaged Thermo Fisher Scientific (“Thermo Fisher”), the world leader in serving science, to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, the Company’s proprietary deuterated psilocin program in Phase 3 development for the adjuncti

GSK plc, a leading clinical-stage biopharmaceutical company developing precision therapies for patients with serious liver disease, and Boston Pharmaceuticals have announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals' lead pipeline drug, efimosfermin alfa. Efimosfermin is a Phase III-ready, potential best-in-class specialty drug for the treatment and slowing of progression of SLD. Under the agreement, GSK will make an upfront payment of $1